Last reviewed · How we verify
Adalimumab SC
Tumour necrosis factor-alpha inhibitor
Tumour necrosis factor-alpha inhibitor Used for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis.
At a glance
| Generic name | Adalimumab SC |
|---|---|
| Sponsor | Centre for Human Drug Research, Netherlands |
| Drug class | TNF-alpha inhibitor |
| Target | TNF-alpha |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 1 |
Mechanism of action
Adalimumab is a fully human monoclonal antibody that binds to tumour necrosis factor-alpha (TNF-alpha), preventing its interaction with cell surface TNF receptors and subsequent inflammatory response.
Approved indications
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Ankylosing Spondylitis
- Crohn's Disease
- Ulcerative Colitis
Common side effects
- Injection site reaction
- Headache
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis (PHASE3)
- A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease (PHASE4)
- Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis (PHASE2)
- A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab (PHASE3)
- Stand UP to Rheumatoid Arthritis (SUPRA) (NA)
- Diabetes Islet Preservation Immune Treatment (PHASE1, PHASE2)
- Personalized Therapies in Inflammatory Complex Disease (PHASE2)
- A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adalimumab SC CI brief — competitive landscape report
- Adalimumab SC updates RSS · CI watch RSS
- Centre for Human Drug Research, Netherlands portfolio CI